Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEP114 in Acute Exacerbation of Persistent Allergic Rhinitis in Children
NCT07835074Phase 3Not yet recruiting
- Sponsor
- EMS
- Start
- Jun 2027
- Primary completion
- Dec 2028
01
Overview
Phase 3, randomised, double-blind trial of DEP114 in persistent allergic rhinitis (PAR) (2 arms), sponsored by EMS. Primary endpoint: Total Nasal Symptom Score at 5 days. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
DEP114
03
Conditions
persistent allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT07835074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835074.